The Business Research Company’s latest report Remdesivir Global Market Report 2020 covers Remdesivir market drivers, Remdesivir market trends, Remdesivir market segments, Remdesivir market growth rate, Remdesivir market major players, and Remdesivir market size. The report provides in-depth analysis of the impact of COVID-19 on the Remdesivir industry, along with revised market numbers due to the effects of the coronavirus.
View Complete Report: https://www.thebusinessresearchcompany.com/report/remdesivir-market-global-report-2020-30-covid-19-growth-and-change
Remdesivir Global Market Report 2020 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market. The chapter also covers markets which have been positively affected by the pandemic.
Request For The Sample Now: https://www.thebusinessresearchcompany.com/sample.aspx?id=3253&type=smp
Gilead’s antiviral remdesivir is being tested in multiple phase 3 clinical trials as a treatment for moderately and severely ill COVID-19 patients. Until January, the company wasn’t manufacturing more than a few doses of its experimental antiviral remdesivir, but then Gilead began advancing remdesivir and is rapidly expanding its production as the research showed that remdesivir might be effective against COVID-19. Gilead spent $50 million on research and development of the drug during the first quarter. Gilead released preliminary results from its clinical trial on remdesivir, showing at least 50% of the patients treated with a five-day dosage of the drug had improved. The clinical trial involved 397 patients with severe cases of COVID-19. Gilead will focus on making remdesivir both accessible and affordable to governments and patients around the world. Taking into consideration the R&D investment and the affordable price range, the drug is expected to generate an estimated $2 billion in sales in 2020. It is expected to grow at 29.02% and reach $4.2 billion in 2023. The revenue will then drop off in subsequent years.
The report covers the remdesivir market’s segments-
1) By Route Of Administration: Oral, Intravenous.
2) By Dosage Form: Tablets, Frozen Solution, Lyophilized Solution.
3) By Distribution Channel: Hospitals, Clinics, Drug Stores/Pharmacies, Online, Others.
Avail up to 50% off on ALL research reports at: https://www.thebusinessresearchcompany.com/global-market-reports Offer applies until Dec 31st.
About The Business Research Company:
The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 20 countries globally.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: [email protected]